In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How Immuno-Oncology Is Turning Biomarker Development On Its Head

Executive Summary

Immuno-oncology’s challenge is to orchestrate a biomarker program in a highly competitive drug development landscape knowing that prior to having significant clinical experience, the program is unlikely to yield the kinds of binary measurements used to define and select a patient population for a targeted therapy.


Related Content

IO Biomarkers: Where Do We Stand In 2017?
Diagnostics In 2016: From Alere To Zika
Bristol Pushes Pedal To Metal In Immuno-Oncology Combo Testing
Roche's Guide To Success In Oncology
FDA, PD-1 Inhibitor Sponsors Discussing Real-World Study
Which Path Forward For Foundation Medicine?
Industry, Cancer Groups Draft Blueprint For PD-1 Companion Dx Approvals
Immunotherapy: Big Pharma’s Seductive Embrace


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts